Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities

References

• Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015;74(9):1706–1713. doi:10.1136/annrheumdis-2013-205171
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Marozoff S, Li L, Sayre EC, Zubieta JAA. All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study. Rheumatol. 2022;61(1):367–376. doi:10.1093/rheumatology/keab362
   Web of Science ®Google Scholar
• Rovin BH. Systemic Lupus Erythematosus. 5th ed. Academic Press; 2011.
   Google Scholar
• Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatol. 2015;55(2):252–262. doi:10.1093/rheumatology/kev311
   PubMed Web of Science ®Google Scholar
• Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004;3(6):423–453. doi:10.1016/j.autrev.2004.04.002
   PubMed Web of Science ®Google Scholar
• Merrell M. Determination of prognosis in chronic disease illustrated by Systemic Lupus Erythematosus. J Chronic Dis. 1853;1:12–32. doi:10.1136/bmj.s3-1.6.117
   Google Scholar
• Ward MM. Changes in the incidence of End-Stage Renal Disease Due To Lupus Nephritis in the United States, 1996 – 2004. J Rheumatol. 2010;36(1):63–67. doi:10.3899/jrheum.080625
   Web of Science ®Google Scholar
• Tektonidou MG, Dasgupta A, Ward MM. Risk of End-Stage Renal Disease in Patients with Lupus Nephritis, 1971-2015: a Systematic Review and Bayesian Meta-Analysis. Arthritis Rheumatol. 2016;68(6):1432–1441. doi:10.1002/art.39594
   PubMed Web of Science ®Google Scholar
• Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatol. 2011;1424–1430. doi:10.1093/rheumatology/ker101
   PubMed Web of Science ®Google Scholar
• Houssiau FA, D’Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083–2089. doi:10.1136/ard.2010.131995
   PubMed Web of Science ®Google Scholar
• Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases-past, present and future. Nat Rev Rheumatol. 2017;13(7):443–448. doi:10.1038/nrrheum.2017.95
   PubMed Web of Science ®Google Scholar
• Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009;24(12):3717–3723. doi:10.1093/ndt/gfp336
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–1226. doi:10.1002/art.34359
   PubMed Web of Science ®Google Scholar
• Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8(3):1–9. doi:10.1186/ar1954
   Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–233. doi:10.1002/art.27233
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117–1128. doi:10.1056/nejmoa2001180
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797–808. doi:10.1002/acr.21664
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):S713–S723. doi:10.1136/annrheumdis-2020-216924
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, et al. Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus. N Engl J Med. 2003;349(16):1526–1533. doi:10.1056/NEJMoa021933
   PubMed Web of Science ®Google Scholar
• Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24(9):1357–1366. doi:10.1681/ASN.2013010026
   PubMed Web of Science ®Google Scholar
• Canny SP, Jackson SW. B Cells in Systemic Lupus Erythematosus: from Disease Mechanisms to Targeted Therapies. Rheum Dis Clin North Am. 2021;47(3):395–413. doi:10.1016/j.rdc.2021.04.006
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Manfroi B, Dörner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(2):98–108. doi:10.1038/s41584-020-00544-4
   PubMed Web of Science ®Google Scholar
• Liarski VM, Kaverina N, Chang A, et al. Cell Distance Mapping Identifies Functional T Follicular Helper Cells in Inflamed Human Renal Tissue. Sci Transl Med. 2014;6(230). doi:10.1126/scitranslmed.3008146
   PubMed Web of Science ®Google Scholar
• Ohmura K. Which is the best SLE activity index for clinical trials? Mod Rheumatol. 2021;31(1):20–28. doi:10.1080/14397595.2020.1775928
   PubMed Web of Science ®Google Scholar
• Luijten KMAC, Tekstra J, Bijlsma JWJ, Bijl M. The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment. Autoimmun Rev. 2012;11(5):326–329. doi:10.1016/j.autrev.2011.06.011
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2005;44(7):902–906. doi:10.1093/rheumatology/keh624
   PubMed Web of Science ®Google Scholar
• Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789–796. doi:10.1016/j.kint.2017.11.023
   PubMed Web of Science ®Google Scholar
• Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1–S276. doi:10.1016/j.kint.2021.05.021
   PubMed Web of Science ®Google Scholar
• Rojas-Rivera JE, García-Carro C, Ávila AI, et al. Documento de consenso del Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN) para el diagnóstico y tratamiento de la nefritis lúpica. Nefrología. 2023;43(1):6–47. doi:10.1016/j.nefro.2022.10.005
   PubMed Web of Science ®Google Scholar
• Draft PR. Kdigo 2023 Clinical Practice Guideline for the Management of Lupus Nephritis Confidential. Do Not Distribute Public Review Draft. 2023:56.
   Google Scholar
• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–28. doi:10.1136/ard.2008.101766
   PubMed Web of Science ®Google Scholar
• Heo Y-A. Voclosporin: first Approval. Drugs. 2021;81(5):605–610. doi:10.1007/s40265-021-01488-z
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Highlights of prescribing information: BENLYSTA (belimumab). Available from: https://gskpro.com/content/dam/global/%0Dhcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PIMG-%0DIFU.PDF. Accessed July 4, 2023.
   Google Scholar
• NHS England. Clinical Commissioning Policy Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children [200402P] Commissioning Position; 2020. Available from: https://www.england.nhs.uk/wp-content/uploads/2020/07/Rituximab-for-refractory-Systemic-Lupus-Erythematosus-in-adults-and-post-pubescent-children-2.pdf. Accessed July 4, 2023.
   Google Scholar
• Guerreiro Castro S, Isenberg DA. Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Ther Adv Musculoskelet Dis. 2017;9(3):75–85. doi:10.1177/1759720X17690474
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403–413. doi:10.1016/j.kint.2021.08.027
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis. Clin J Am Soc Nephrol. 2022;17(11):1620–1630. doi:10.2215/cjn.02520322
   PubMed Web of Science ®Google Scholar
• Gatto M, Saccon F, Andreoli L, et al. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. J Autoimmun. 2021;124(September):102729. doi:10.1016/j.jaut.2021.102729
   PubMedGoogle Scholar
• Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs. 2002;13(1):S3–S10. doi:10.1097/00001813-200211002-00002
   PubMedGoogle Scholar
• Cambridge G, Leandro MJ, Teodorescu M, et al. B Cell Depletion Therapy in Systemic Lupus Erythematosus Effect on Autoantibody and Antimicrobial Antibody Profiles. J Am College Rheumatol. 2006;54(11):3612–3622. doi:10.1002/art.22211
   Google Scholar
• Sciascia S, Rubini E, Radin M, Cecchi I, Rossi D, Roccatello D. Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. Ann Rheumatic Dis. 2018;1(3):1–2. doi:10.1136/annrheumdis-2018-213496
   Google Scholar
• Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 2001;40(2):205–211. doi:10.1093/rheumatology/40.2.205
   PubMed Web of Science ®Google Scholar
• Habibi MA, Alesaeidi S, Zahedi M, Hakimi Rahmani S, Piri SM, Tavakolpour S. The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review. Biology. 2022;11:1767. doi:10.3390/biology11121767
   PubMedGoogle Scholar
• Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12(6):367–372. doi:10.1038/nrrheum.2016.18
   PubMed Web of Science ®Google Scholar
• Lazarus MN, Turner-Stokes T, Chavele KM, Isenberg DA, Ehrenstein MR. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatol. 2012;51(7):1208–1215. doi:10.1093/rheumatology/ker526
   PubMed Web of Science ®Google Scholar
• Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15(SUPPL.1):1–8. doi:10.1186/ar3908
   Web of Science ®Google Scholar
• Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013;28(1):106–111. doi:10.1093/ndt/gfs285
   PubMed Web of Science ®Google Scholar
• Li K, Yu Y, Gao Y, Zhao F, Liang Z, Gao J. Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: a Systematic Review and Network Meta-Analysis. Front Immunol. 2022;13(April):1–9. doi:10.3389/fimmu.2022.859380
   Google Scholar
• Díaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357–364. doi:10.1016/j.autrev.2011.10.009
   PubMed Web of Science ®Google Scholar
• Kronbichler A, Brezina B, Gauckler P, Quintana LF, Jayne DRW. Refractory lupus nephritis: when, why and how to treat. Autoimmun Rev. 2019;18(5):510–518. doi:10.1016/j.autrev.2019.03.004
   PubMed Web of Science ®Google Scholar
• Iwata S, Saito K, Hirata S, et al. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus. 2018;27(5):802–811. doi:10.1177/0961203317749047
   PubMed Web of Science ®Google Scholar
• Melander C, Sallée M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009;4(3):579–587. doi:10.2215/CJN.04030808
   PubMed Web of Science ®Google Scholar
• Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology. 2012;51(3):476–481. doi:10.1093/rheumatology/ker337
   PubMed Web of Science ®Google Scholar
• Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017;4(1):1–9. doi:10.1136/lupus-2016-000182
   Google Scholar
• Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280–1286. doi:10.1136/annrheumdis-2012-202844
   PubMed Web of Science ®Google Scholar
• Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100–107. doi:10.1136/annrheumdis-2021-220920
   PubMed Web of Science ®Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368–2379. doi:10.1002/art.38037
   PubMed Web of Science ®Google Scholar
• Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell - mediated B-cell cytotoxicity. Blood. 2010;115(22):4393–4402. doi:10.1182/blood-2009-06-225979
   PubMed Web of Science ®Google Scholar
• Reddy V, Klein C, Isenberg DA, et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatol. 2017;56(7):1227–1237. doi:10.1093/rheumatology/kex067
   PubMed Web of Science ®Google Scholar
• Rigby W, Tony HP, Oelke K, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012;64(2):350–359. doi:10.1002/art.33317
   PubMed Web of Science ®Google Scholar
• Zhang B. Ofatumumab. InMAbs. 2009;1(4):326–331.
   Google Scholar
• Masoud S, McAdoo SP, Bedi R, Cairns TD, Lightstone L. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatol. 2018;57(7):1156–1161. doi:10.1093/rheumatology/key042
   PubMed Web of Science ®Google Scholar
• Haarhaus ML, Svenungsson E, Gunnarsson I. Ofatumumab treatment in lupus nephritis patients. Clin Kidney J. 2016;9(4):552–555. doi:10.1093/ckj/sfw022
   PubMed Web of Science ®Google Scholar
• Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2672–2679. doi:10.1002/art.38074
   PubMed Web of Science ®Google Scholar
• Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119(5):1066–1073. doi:10.1172/JCI38010
   PubMed Web of Science ®Google Scholar
• Susianti H, Hanggara DS, Lestari KD, Purnamasari P, Aprilia A. Analysis of TNF-like weak inducer of apoptosis for detecting lupus nephritis. Comp Clin Path. 2022;31(2):313–316. doi:10.1007/s00580-022-03334-4
   PubMedGoogle Scholar
• Smith KGC, Clatworthy MR. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10(5):328–343. doi:10.1038/nri2762
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, Phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):323–331. doi:10.1136/annrheumdis-2015-207653
   PubMed Web of Science ®Google Scholar
• Merrill JT, Van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled stu. Ann Rheum Dis. 2016;75(2):332–340. doi:10.1136/annrheumdis-2015-207654
   PubMed Web of Science ®Google Scholar
• Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW. The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two Phase 3 randomized, clinical trials. Lupus. 2016;25(14):1597–1601. doi:10.1177/0961203316650734
   PubMed Web of Science ®Google Scholar
• Stohl W, Merrill JT, Looney RJ, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015;17(1):215. doi:10.1186/s13075-015-0741-z
   PubMedGoogle Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):1–7. doi:10.1186/ar3738
   PubMed Web of Science ®Google Scholar
• Gordon C, Bassi R, Chang P, et al. Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. Rheumatol Adv Pract. 2019;3(2):1–12. doi:10.1093/rap/rkz021
   Google Scholar
• Isenberg D, Cogollo E, Amaral-Silva M. Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. 2015;8:1331. doi:10.2147/DDDT.S71276
   Web of Science ®Google Scholar
• Wang L, Li J, Xu D, Fang J, Van Vollenhoven R, Zhang F. Efficacy and safety of Telitacicept, a novel BLyS/April Dual Inhibitor, In Patients With Systemic Lupus Erythematosus: a Phase 3, Randomized, Placebo-Controlled 52-week Study. Ann Rheum Dis. 2023;82(Suppl 1):90.2–91. doi:10.1136/annrheumdis-2023-eular.1727
   Google Scholar
• Merrill JT, Shanahan WR, Scheinberg M. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77(6):883–889. doi:10.1136/annrheumdis-2018-213032
   PubMed Web of Science ®Google Scholar
• Kayagaki N, Yan M, Seshasayee D, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity. 2002;17(4):515–524. doi:10.1016/S1074-7613(02)00425-9
   PubMed Web of Science ®Google Scholar
• Kraaij T, Kamerling SWA, de Rooij ENM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45–54. doi:10.1016/j.jaut.2018.03.003
   PubMed Web of Science ®Google Scholar
• Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol. 2021;73(1):121–131. doi:10.1002/art.41466
   PubMed Web of Science ®Google Scholar
• Shipa M, Embleton-Thirsk A, Parvaz M, et al. Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus A Randomized Controlled Trial. Ann Intern Med. 2021;174(12):1647–1657. doi:10.7326/M21-2078
   PubMed Web of Science ®Google Scholar
• Aranow C, Allaart C, Amoura Z, et al. Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: the Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study [Abstract]. Arthritis Rheumatol. 2021;73(suppl 10):456.
   Google Scholar
• Kraaij T, Arends EJ, Van Dam LS, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant. 2021;36(8):1474–1483. doi:10.1093/ndt/gfaa117
   PubMed Web of Science ®Google Scholar
• van Schaik M, Arends EJ, Soonawala D, et al. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. Trials. 2022;23(1). doi:10.1186/s13063-022-06874-w
   PubMedGoogle Scholar
• Furie R, Malvar A, Navarra SV, Smirnakis K, Kong J, Franchimont SF. Evaluation of the Efficacy, Safety, and Tolerability of BIIB023 As an Adjunct to Standard of Care in Subjects with Lupus Nephritis [abstract]. Arthritis Rheumatol. 2016;68(suppl):75.
   Google Scholar
• Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52(2):501–513. doi:10.1002/art.20858
   PubMed Web of Science ®Google Scholar
• Liu Z, Liu S, Zhang Y, et al. Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production. Cell Immunol. 2021;368:104420. doi:10.1016/j.cellimm.2021.104420
   PubMed Web of Science ®Google Scholar
• Furie RA, Bruce IN, Dörner T, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatol. 2021;60(11):5397–5407. doi:10.1093/rheumatology/keab381
   PubMed Web of Science ®Google Scholar
• Pimentel-Quiroz VR, Ugarte-Gil MF, Alarcón GS. Abatacept for the treatment of systemic lupus erythematosus. Expert Opin Investig Drugs. 2016;25(4):493–499. doi:10.1517/13543784.2016.1154943
   PubMed Web of Science ®Google Scholar
• Schiffer L, Sinha J, Wang X, et al. Short Term Administration of Costimulatory Blockade and Cyclophosphamide Induces Remission of Systemic Lupus Erythematosus Nephritis in NZB/W F1 Mice by a Mechanism Downstream of Renal Immune Complex Deposition. J Immunol. 2003;171(1):489–497. doi:10.4049/jimmunol.171.1.489
   PubMed Web of Science ®Google Scholar
• Meyers EC, Solorzano BR, James J, Ganzer PD, Elaine S. Treatment of Lupus Nephritis With Abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol. 2014;66(11):3096–3104. doi:10.1002/art.38790
   PubMed Web of Science ®Google Scholar
• Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of Abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379–389. doi:10.1002/art.38260
   PubMed Web of Science ®Google Scholar
• Dooley MA, Appel GB, Furie R, et al. A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept or Placebo on Standard of Care in Patients with Active Class III or IV Lupus Nephritis [abstract]. Arthritis Rheumatol. 2018;J70(suppl 9):3306. doi:10.1136/annrheumdis-2018-eular.3306
   Google Scholar
• Danion F, Rosine N, Belkhir R, et al. Efficacy of Abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease. Lupus. 2016;25(13):1440–1447. doi:10.1177/0961203316640911
   PubMed Web of Science ®Google Scholar
• Merrill JT, June J, Koumpouras F, et al. Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2018;70(suppl 10):L14.
   Google Scholar
• Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatol. 2013;52(7):1313–1322. doi:10.1093/rheumatology/ket129
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73(1):183–190. doi:10.1136/annrheumdis-2012-202760
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Wallace DJ, Furie RA, et al. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. Arthritis Rheumatol. 2017;69(2):362–375. doi:10.1002/art.39856
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Dörner T, Bootsma H, et al. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren’s Syndrome: post Hoc Analyses From the EMBODY Trials. Arthritis Rheumatol. 2018;70(5):763–773. doi:10.1002/art.40425
   PubMed Web of Science ®Google Scholar
• Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2020;383(12):1149–1155. doi:10.1056/nejmoa2023325
   PubMed Web of Science ®Google Scholar
• Chalmers SA, Ramachandran RA, Garcia SJ, et al. The CD6/ALCAM pathway promotes lupus nephritis via T cell–mediated responses. J Clin Invest. 2022;132(1):1–17. doi:10.1172/JCI147334
   Web of Science ®Google Scholar
• Kong W, Deng W, Sun Y, et al. Increased expression of bruton’s tyrosine kinase in peripheral blood is associated with lupus nephritis. Clin Rheumatol. 2018;37(1):43–49. doi:10.1007/s10067-017-3717-3
   PubMed Web of Science ®Google Scholar
• Lorenzo-Vizcaya A, Fasano S, Isenberg DA. Bruton’s Tyrosine Kinase Inhibitors: a New Therapeutic Target for the Treatment of SLE? ImmunoTargets and Therapy. 2020;9:105–110. doi:10.2147/ITT.S240874
   PubMed Web of Science ®Google Scholar
• Isenberg D, Furie R, Jones NS, et al. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021;73(10):1835–1846. doi:10.1002/art.41811
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Dörner T, Pisetsky DS, et al. Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial. ACR Open Rheumatol. 2023;5(1):38–48. doi:10.1002/acr2.11511
   PubMedGoogle Scholar
• Neys SFH, Rip J, Hendriks RW, Corneth OBJ. Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease. Drugs. 2021;81(14):1605–1626. doi:10.1007/s40265-021-01592-0
   PubMed Web of Science ®Google Scholar
• Zhou M, Guo C, Li X, et al. JAK/STAT signaling controls the fate of CD8+CD103+ tissue-resident memory T cell in lupus nephritis. J Autoimmun. 2020;109. doi:10.1016/j.jaut.2020.102424
   Web of Science ®Google Scholar
• Garufi C, Mancuso S, Spinelli FR, et al. Janus kinases inhibitors for treating patients with rhupus. Jt Bone Spine. 2020;87(6):673–674. doi:10.1016/j.jbspin.2020.05.010
   PubMed Web of Science ®Google Scholar
• Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2023;75(2):242–252. doi:10.1002/art.42391
   PubMed Web of Science ®Google Scholar
• Dörner T, van Vollenhoven RF, Doria A, et al. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Res Ther. 2022;24(1):112. doi:10.1186/s13075-022-02794-x
   PubMed Web of Science ®Google Scholar
• Petri M, Bruce IN, Dörner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023;401(10381):1011–1019. doi:10.1016/S0140-6736(22)02546-6
   PubMedGoogle Scholar
• Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401(10381):1001–1010. doi:10.1016/S0140-6736(22)02607-1
   PubMedGoogle Scholar
• Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748–755. doi:10.1038/nm1763
   PubMed Web of Science ®Google Scholar
• Segarra A, Arredondo KV, Jaramillo J, et al. Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus. 2020;29(2):118–125. doi:10.1177/0961203319896018
   PubMed Web of Science ®Google Scholar
• Sjöwall C, Hjorth M, Eriksson P. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. Lupus. 2017;26(12):1333–1338. doi:10.1177/0961203317691371
   PubMed Web of Science ®Google Scholar
• Hiepe F, Alexander T, Peukert R, et al. Refractory SLE patients respond to the proteasome inhibitor bortezomib. Ann Rheum Dis. 2012;71(Suppl 1):A15.3–A16. doi:10.1136/annrheumdis-2011-201230.34
   Google Scholar
• Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012;12(1):257–270. doi:10.1016/j.intimp.2011.11.019
   PubMed Web of Science ®Google Scholar
• Ichikawa HT, Conley T, Muchamuel T, et al. Novel Proteasome Inhibitors Have a Beneficial Effect in Murine Lupus via the dual inhibition of Type I Interferon and autoantibody secreting cells. Arthritis Rheum. 2012;64(2):493–503. doi:10.1002/art.33333
   PubMed Web of Science ®Google Scholar
• Abdel Galil SM, Ezzeldin N, El-Boshy ME. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine. 2015;76(2):280–287. doi:10.1016/j.cyto.2015.05.007
   PubMed Web of Science ®Google Scholar
• Satoh Y, Nakano K, Yoshinari H, et al. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus. 2018;27(7):1202–1206. doi:10.1177/0961203318762598
   PubMed Web of Science ®Google Scholar
• Costa R, Antunes P, Salvador P, Oliveira P, Marinho A. Secukinumab on Refractory Lupus Nephritis. Cureus. 2021;13(8):15–19. doi:10.7759/cureus.17198
   Web of Science ®Google Scholar
• van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: results of a Phase II Open-label Extension Study. J Rheumatol. 2022;49(4):380–387. doi:10.3899/jrheum.210805
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Kalunian KC, Dörner T, et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. 2022;81(11):1556–1563. doi:10.1136/ard-2022-222858
   PubMed Web of Science ®Google Scholar
• Sun H, Liu W, Shao J, Xu H, Xiao K, Sheng G. Study on immunoregulation by interleukin-1 receptor antagonist in NZB/W F mice. J Tongji Med Univ. 1997;17(1):18–20. doi:10.1007/bf02887995
   PubMedGoogle Scholar
• Brugos B, Kiss E, Dul C, et al. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. Hum Immunol. 2010;71(9):874–877. doi:10.1016/j.humimm.2010.06.004
   PubMed Web of Science ®Google Scholar
• Dein E, Ingolia A, Connolly C, Manno R, Timlin H. Anakinra for Recurrent Fevers in Systemic Lupus Erythematosus. Cureus. 2018;10(12):2010–2012. doi:10.7759/cureus.3782
   Web of Science ®Google Scholar
• Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005;64(4):630–633. doi:10.1136/ard.2004.025858
   PubMed Web of Science ®Google Scholar
• Humrich J, von Spee-Mayer C, Siegert E, et al. Low-Dose IL-2 Therapy in Refractory SLE: results from Single Center Phase I/IIa Clinical Trial [abstract]. Arthritis Rheumatol. 2016:68.
   Web of Science ®Google Scholar
• Cash H, Relle M, Menke J, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Fas lpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol. 2010;37(1):60–70. doi:10.3899/jrheum.090194
   PubMed Web of Science ®Google Scholar
• Rovin BH, van Vollenhoven RF, Aranow C, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. Arthritis Rheumatol. 2016;68(9):2174–2183. doi:10.1002/art.39722
   PubMed Web of Science ®Google Scholar
• Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951–2962. doi:10.1002/art.22044
   PubMedGoogle Scholar
• Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod Rheumatol. 2021;31(1):1–12. doi:10.1080/14397595.2020.1812201
   PubMed Web of Science ®Google Scholar
• Jayne D, Rovin B, Mysler EF, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022:496–506. doi:10.1136/annrheumdis-2021-221478
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909–1916. doi:10.1136/annrheumdis-2015-208562
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A. 1996;93(16):8563–8568. doi:10.1073/pnas.93.16.8563
   PubMed Web of Science ®Google Scholar
• Lourenço V, Wong M, Hahn BH, Palma-Diaz MF, Skaggs BJ. Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells. Arthritis Rheumatol. 2014;66(3):674–685. doi:10.1002/art.38259
   PubMed Web of Science ®Google Scholar
• Jayne D, Appel G, Chan TM, Barkay H, Weiss R, Wofsy D. LB0003 A Randomized Controlled Study of Laquinimod in Active Lupus Nephritis Patients in Combination with Standard of Care. Ann Rheum Dis. 2013;72(Suppl 3):A164.2–A164. doi:10.1136/annrheumdis-2013-eular.528
   Google Scholar
• Xia Y, Fang X, Dai X, et al. Iguratimod ameliorates nephritis by modulating the Th17/Treg paradigm in pristane-induced lupus. Int Immunopharmacol. 2021;96(March). doi:10.1016/j.intimp.2021.107563
   Google Scholar
• Kang Y, Yan Q, Fu Q, et al. Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study. Arthritis Res Ther. 2020;22(1):1–8. doi:10.1186/s13075-020-02154-7
   PubMed Web of Science ®Google Scholar
• Yan Q, Du F, Kang Y, et al. Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study). Trials. 2021;22(1):1–13. doi:10.1186/s13063-021-05475-3
   PubMed Web of Science ®Google Scholar
• Kawasaki Y. Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol. 2009;2009. doi:10.1155/2009/681482
   PubMedGoogle Scholar
• Tanaka Y, Yoshikawa N, Hattori S, et al. Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial. Pediatr Nephrol. 2010;25(5):877–882. doi:10.1007/s00467-009-1341-4
   PubMed Web of Science ®Google Scholar
• Nishi E, Kameda H, Ogawa H, et al. Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. Mod Rheumatol. 2013;23(1):97–103. doi:10.1007/s10165-012-0645-6
   PubMed Web of Science ®Google Scholar
• Zhang M, Xing CY, Liu J. Study of the efficacy of mizoribine in lupus nephritis in Chinese patients. Rheumatol Int. 2013;33(11):2737–2742. doi:10.1007/s00296-013-2804-2
   PubMed Web of Science ®Google Scholar
• Kagawa H, Yamanaka R, Hiromasa T. First-line Combination Strategy Provides Favorable 5-year Outcomes for Patients with Lupus Nephritis: a Single-center Observational Study. Acta Med Okayama. 2022;76(5):547–555. doi:10.18926/AMO/64036
   PubMed Web of Science ®Google Scholar
• Fuke T, Abe Y, Hibino S, et al. Mizoribine requires individual dosing due to variation of bioavailability. Pediatr Int. 2012;54(6):885–891. doi:10.1111/j.1442-200X.2012.03733.x
   PubMed Web of Science ®Google Scholar
• Tanaka H, Aizawa T, Watanabe S, Oki E, Tsuruga K, Imaizumi T. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. Lupus. 2014;23(8):813–818. doi:10.1177/0961203314528553
   PubMed Web of Science ®Google Scholar
• Kagawa H, Hiromasa T, Yamanaka R, et al. The first year results of mizoribine/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis. Clin Exp Nephrol. 2018;22(6):1371–1378. doi:10.1007/s10157-018-1597-8
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Okada K, Yoshida H, Yagi N. Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results. Mod Rheumatol. 2018;28(1):85–94. doi:10.1080/14397595.2017.1349573
   PubMed Web of Science ®Google Scholar
• Peng L, Wu C, Hong R, et al. Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. Ther Adv Musculoskelet Dis. 2020;12(6):1759720X2095333. doi:10.1177/1759720X20953336
   Google Scholar
• Burt RK, Han X, Gozdziak P, et al. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid- dependent systemic lupus erythematosus: effect of conditioning regimen on outcome. Bone Marrow Transplant. 2018. doi:10.1038/s41409-018-0173-x
   PubMed Web of Science ®Google Scholar
• Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010;95(2):284–292. doi:10.3324/haematol.2009.013458
   PubMed Web of Science ®Google Scholar
• Burt RK. Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus. JAMA. 2006;295(5):527. doi:10.1001/jama.295.5.527
   PubMed Web of Science ®Google Scholar
• Gu F, Wang D, Zhang H, et al. Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin Rheumatol. 2014;33(11):1611–1619. doi:10.1007/s10067-014-2754-4
   PubMed Web of Science ®Google Scholar
• Wang D, Li J, Zhang Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16(2). doi:10.1186/ar4520
   Web of Science ®Google Scholar
• Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436–1439. doi:10.1136/annrheumdis-2017-211073
   PubMed Web of Science ®Google Scholar
• Mougiakakos D, Krönke G, Völkl S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021;385(6):567–569. doi:10.1056/NEJMc2107725
   PubMed Web of Science ®Google Scholar
• Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124–2132. doi:10.1038/s41591-022-02017-5
   PubMed Web of Science ®Google Scholar